Here’s Why DexCom (DXCM) Surged in Q4

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Focus Growth Strategy” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, Aristotle Atlantic’s Focus Growth strategy posted a return of 2.66% net of fees compared to a 2.20% return for the Russell 1000 Growth Index. Stock selection and allocation led the strategy to outperform in the quarter relative to its benchmark. In addition, you can check the top 5 holdings of the fund to know its best picks in 2022.

Aristotle Atlantic Focus Growth Strategy highlighted stocks like DexCom, Inc. (NASDAQ:DXCM) in the Q4 2022 investor letter. Headquartered in San Diego, California, DexCom, Inc. (NASDAQ:DXCM) is a medical device company. On April 5, 2023, DexCom, Inc. (NASDAQ:DXCM) stock closed at $112.82 per share. One-month return of DexCom, Inc. (NASDAQ:DXCM) was 0.07%, and its shares lost 11.43% of their value over the last 52 weeks. DexCom, Inc. (NASDAQ:DXCM) has a market capitalization of $43.747 billion.

Aristotle Atlantic Focus Growth Strategy made the following comment about DexCom, Inc. (NASDAQ:DXCM) in its Q4 2022 investor letter:

“DexCom, Inc. (NASDAQ:DXCM) shares were strong following a solid third quarter earnings announcement as well as news of additional Medicare reimbursement and that the FDA has approved their next generation device, G7, in early December.”

DexCom, Inc. (NASDAQ:DXCM) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 70 hedge fund portfolios held DexCom, Inc. (NASDAQ:DXCM) at the end of the fourth quarter, which was 62 in the previous quarter.

We discussed DexCom, Inc. (NASDAQ:DXCM) in another article and shared the list of best medical stocks to invest in. In addition, please check out our hedge fund investor letters Q4 2022 page for more investor letters from hedge funds and other leading investors.

Suggested Articles:

Disclosure: None. This article is originally published at Insider Monkey.